

# *APOE* polymorphisms influence longitudinal lipid trends preceding intracerebral hemorrhage

OPEN

Chia-Ling Phuah, MD  
Miriam R. Raffeld, BA  
Alison M. Ayres, BA  
M. Edip Gurol, MD, MSc  
Anand Viswanathan,  
MD, PhD  
Steven M. Greenberg,  
MD, PhD  
Alessandro Biffi, MD  
Jonathan Rosand, MD,  
MSc  
Christopher D. Anderson,  
MD, MMSc

Correspondence to  
Dr. Anderson:  
cdanderson@mgh.harvard.edu

## ABSTRACT

**Objective:** We sought to determine whether *APOE* genotype influences a previously observed decline in serum total cholesterol (TC) and low-density lipoprotein (LDL) levels preceding primary intracerebral hemorrhage (ICH), as a potential demonstration of nonamyloid mechanisms of *APOE* in ICH risk.

**Methods:** We performed a single-center retrospective longitudinal analysis using patients with known *APOE* genotype drawn from an ongoing cohort study of ICH. Serum lipid measurements for TC, triglycerides (TGs), LDL, and high-density lipoprotein (HDL) collected within 2 years before and after index ICH were extracted from electronic medical records. Piecewise linear mixed-effects models were used to compare *APOE* allele-specific effects on temporal serum lipid trends in ICH. Demographics, medical history, medications, and health maintenance data were included as fixed effects. Inter- and intraindividual variations in lipid levels were modeled as random effects.

**Results:** A total of 124 ICH cases were analyzed. *APOE*  $\epsilon$ 4 carriers had greater rates of decline in serum TC and LDL within 6 months preceding ICH (TC:  $-7.30$  mg/dL/mo,  $p = 0.0035$ ; LDL:  $-8.44$  mg/dL/mo,  $p = 0.0001$ ). Conversely, serum TC and LDL levels in *APOE*  $\epsilon$ 2 carriers were unchanged within the same time period. *APOE* genotype had no associations with serum HDL or TG trends.

**Conclusions:** *APOE* allele status predicts serum TC and LDL changes preceding acute ICH. Our results have implications for ongoing efforts in dissecting the role of dyslipidemia in cerebrovascular disease risk. *APOE* genotype-specific influence on lipid trends provides a clue for one mechanism by which *APOE* may influence risk of ICH. Further characterization of the metabolic roles of *APOE* is needed to improve the understanding of *APOE* biology in cerebrovascular disease risk. *Neurol Genet* 2016;2:e81; doi: 10.1212/NXG.000000000000081

## GLOSSARY

**HDL** = high-density lipoprotein; **ICH** = intracerebral hemorrhage; **LDL** = low-density lipoprotein; **PLME** = piecewise linear mixed-effects; **TC** = total cholesterol; **TG** = triglyceride.

Primary intracerebral hemorrhage (ICH) accounts for 10%–15% of all strokes<sup>1</sup> but is the most severe form of acute cerebrovascular disease, with 90-day mortality rates of 40%–50% and with fewer than a third of survivors regaining functional independence by 12 months.<sup>2,3</sup> Previous studies have established  $\epsilon$ 2/ $\epsilon$ 4 alleles of the *APOE* gene as potent determinants of ICH risk, severity, and outcome.<sup>4–6</sup> *APOE*  $\epsilon$ 2 and  $\epsilon$ 4 are associated with increased risk of ICH occurring in the lobar regions of the brain, whereas *APOE*  $\epsilon$ 4, but not  $\epsilon$ 2, is associated with risk of nonlobar ICH.<sup>4,7</sup> Separately, several epidemiologic studies have also observed an association between serum lipid levels and ICH risk and outcome.<sup>8–16</sup> Hypercholesterolemia has been associated

Supplemental data  
at [Neurology.org/ng](http://Neurology.org/ng)

From the Division of Neurocritical Care and Emergency Neurology (C.-L.P., J.R., C.D.A.), Center for Human Genetic Research (C.-L.P., M.R.R., A.B., J.R., C.D.A.), The J. Philip Kistler Stroke Research Center (A.M.A., M.E.G., A.V., S.M.G., J.R., C.D.A.), Hemorrhagic Stroke Research Group (A.M.A., M.E.G., A.V., S.M.G., J.R., C.D.A.), Division of Behavioral Neurology (A.B.), Division of Psychiatry (A.B.), Department of Psychiatry, Massachusetts General Hospital, Boston; and Program in Medical and Population Genetics (C.-L.P., A.B., J.R., C.D.A.), Broad Institute, Cambridge, MA.

Funding information and disclosures are provided at the end of the article. Go to [Neurology.org/ng](http://Neurology.org/ng) for full disclosure forms. The Article Processing Charge was paid by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

with reduced risk of ICH,<sup>8–13</sup> fewer cerebral microbleeds, and improved outcome after ICH.<sup>15,16</sup> However, despite known functions of *APOE* gene products in lipid transport and regulating circulating lipid levels,<sup>17</sup> the biological mechanisms mediating the roles of *APOE* and serum lipids on ICH risk remain unclear. A previous finding that serum low-density lipoprotein (LDL) mediates *APOE*  $\epsilon 4$ -associated nonlobar ICH risk<sup>7</sup> suggests that the effect of *APOE* on ICH may be at least in part because of its effect on lipids.


We have recently demonstrated that ICH is preceded by declines in serum total cholesterol (TC) and LDL levels.<sup>18</sup> We hypothesized that *APOE* genotype may influence these temporal lipid trends in ICH and tested this hypothesis by investigating *APOE* allele-specific effects on changes in serum lipid trends over time

in a cohort of ICH patients with longitudinal lipid data.

**METHODS Study design.** Patients were drawn from an ongoing prospective longitudinal cohort study of primary ICH at Massachusetts General Hospital (MGH)<sup>19</sup> (figure 1). All aspects of this study were approved by the MGH Institutional Review Board (IRB), and written informed consent was obtained from all patients or their legal guardians before study participation.

**Patient selection.** Individuals enrolled in the MGH longitudinal ICH study presenting to the MGH Emergency Department between June 1993 and June 2014 were screened for eligibility for the present study based on the following: (1) availability of *APOE* genotype, (2) survival up to 2 years after ICH, and (3) possession of at least 3 serum lipid values for each lipid fraction of interest including TC, LDL, triglycerides (TGs), and high-density lipoprotein (HDL) drawn >6 months apart within 24 months before and after the date of acute ICH. Patients with recurrent ICH or other non-ICH hospitalization events during the time period of interest were excluded to minimize confounding by variations in serum lipid levels during periods of acute illness.<sup>20,21</sup>

**Figure 1** Study cohort and analysis plan



MGH-ICH Database = Massachusetts General Hospital-based patients in the Genetics of Cerebral Hemorrhage on Anti-coagulation Study; ICH = intracerebral hemorrhage.

**Data collection.** All included individuals had serum lipid values (TC, TG, LDL, and HDL) extracted via semiautomated review of hospital electronic medical records (EMRs). Because ICH events are observed at random, to make comparisons for variations in serum lipid trends before and after ICH, individual ICH events were time-locked into a balanced design with equal time periods of 24 months before and after the acute event. Serum lipid values were obtained for 6-month time intervals (4 intervals before and 4 intervals after the ICH event). Serum lipid values were segregated into their respective time intervals based on timing of the measurement in relation to the date of ICH occurrence. Means were obtained for multiple serum lipid measurements within the same time interval.

Clinical data were recorded at the time of index presentation including information on demographics, medical history (including hypertension and diabetes mellitus), pre-ICH medication use, and health maintenance (including cigarette smoking and alcohol use). Statin use within 24 months pre-ICH was determined at the time of ICH presentation using a patient-based questionnaire and scored as “yes/no” binary variables. Validity and reliability of statin use response in the questionnaire were internally assessed by comparisons with medication history obtained from hospital EMR search. A 10% random sampling of the enrolled cohort demonstrated 100% concordance in patients who were statin naive. ICH location was assigned as either lobar or nonlobar based on admission CT scans. Nonlobar ICH was restricted to hemorrhage locations involving the brainstem, thalamus, or basal ganglia, whereas lobar ICH included hemorrhages originating from the cortical-subcortical regions.

**Genotyping.** Study individuals had *APOE* genotype determined previously from blood samples.<sup>4</sup> In brief, peripheral whole blood was collected from study individuals at the time of consent. DNA was isolated from fresh or frozen blood, quantified using a quantification kit (Qiagen, Valencia, CA), and normalized to a concentration of 30 ng/ $\mu$ L. *APOE* genotypes were determined by genotyping 2 variants in *APOE*, rs7412 and rs429358, via 2 separate assays<sup>4</sup> with the subsequent allelic reads from both assays then combined for translation to *APOE* genotypes ( $\epsilon$ 3 $\epsilon$ 3,  $\epsilon$ 3 $\epsilon$ 4,  $\epsilon$ 4 $\epsilon$ 4,  $\epsilon$ 3 $\epsilon$ 2,  $\epsilon$ 2 $\epsilon$ 2, and  $\epsilon$ 2 $\epsilon$ 4).

**Standard protocol approvals, registrations, and patient consents.** This study was performed with approval of the MGH IRB. ICH patients provided informed consent for study participation.

**Statistical methods.** Study individuals were grouped by *APOE*  $\epsilon$ 2 and  $\epsilon$ 4 carrier status (having either 1 or 2 allelic copies of  $\epsilon$ 2 and  $\epsilon$ 4, respectively) with *APOE*  $\epsilon$ 3 $\epsilon$ 3 individuals serving as a reference cohort as the  $\epsilon$ 3 allele is not associated with ICH risk.<sup>4</sup> Patients with  $\epsilon$ 2 $\epsilon$ 4 *APOE* genotype ( $n = 5$ ) were excluded because of an inability to assign a single carrier status. Comparisons of differences in cohort characteristics between  $\epsilon$ 2 or  $\epsilon$ 4 carriers and the reference  $\epsilon$ 3 $\epsilon$ 3 group were made by univariate analyses using unpaired  $t$  test, Mann-Whitney rank sum test, or Fisher exact test, as appropriate. Continuous numeric variables were expressed as mean  $\pm$  SD.

Piecewise linear mixed-effects (PLME) random-coefficient models were used to evaluate *APOE* allele-specific effects on temporal variation in serum lipid trends in ICH patients within prespecified time periods, which are fixed in relation to acute ICH occurrence.<sup>22</sup> This allowed for modeling of change in serum lipid trends in predetermined time intervals of interest to differ within and between  $\epsilon$ 2 or  $\epsilon$ 4 carriers and noncarriers. In a previous case-control analysis comparing ICH patients and non-ICH controls, we demonstrated significant decline in serum lipid trends in the 6-month interval immediately preceding the occurrence of ICH, which was not observed in non-ICH controls.<sup>18</sup> Accordingly, fixed knots were placed at the date of acute ICH and the date 6 months before acute ICH to mark transitions in time periods of interest corresponding to the time period 6–24 months pre-ICH ( $P_1$ ), the time period 0–6 months immediately pre-ICH ( $P_2$ ), and time period 0–24 months post-ICH ( $P_3$ ).

Separate multivariate linear mixed models were constructed for  $\epsilon$ 2 and  $\epsilon$ 4 carriers, with carrier status and covariates whose  $p$  values were  $<0.20$  on univariate analyses or with known potential to influence serum lipid levels included as fixed effects. The final multivariate model was adjusted for variables: age, sex, race, pre-ICH history of hypertension, statin use (yes/no), smoking history (ever smoked), and ICH location. Interindividual and intraindividual variation in serum lipid levels were modeled as random effects. Model validity was examined using a likelihood ratio test. Unstructured covariance was used as the covariance model. Comparisons of the significance in change in serum lipid trends (slope) at the time period of interest,  $P_2$  (0–6 months pre-ICH), by *APOE* allele carrier status were made using the Wald test. Subgroup analyses stratified by ICH location (lobar and nonlobar) for  $\epsilon$ 2 and  $\epsilon$ 4 carrier status were separately performed but not shown because of insufficient statistical power. Significance threshold was set at  $p < 0.05$  (2-tailed) for univariate analyses and at  $p < 0.0125$  (Bonferroni correction for 4 tests) for individual serum lipid fraction mixed-model analyses. All statistical analyses were performed using STATA 10.0 (StataCorp LP, College Station, TX).

**RESULTS Cohort characteristics.** A total of 212 ICH patients enrolled between June 1993 and June 2014 with longitudinal serum lipid levels measured that met our inclusion criteria; 129 of these patients were genotyped for *APOE*. The 83 ICH patients removed because of the absence of *APOE* genotype (figure 1) did not differ in clinical characteristics from the group of patients who ultimately were included in our analyses (table e-1 at Neurology.org/ng). After removing the 5 patients with *APOE*  $\epsilon$ 2/ $\epsilon$ 4, we analyzed 124 individuals including 19  $\epsilon$ 2 carriers, 39  $\epsilon$ 4 carriers, and 66  $\epsilon$ 3/ $\epsilon$ 3 patients (table 1). Compared with the reference group (*APOE*  $\epsilon$ 3 $\epsilon$ 3),  $\epsilon$ 2 carriers were less likely to have a pre-ICH history of hypertension, and

**Table 1** Baseline characteristics of the study cohort

Variable	<i>APOE</i> $\epsilon$ 2 (n = 19)	<i>APOE</i> $\epsilon$ 3/ $\epsilon$ 3 (n = 66)	<i>APOE</i> $\epsilon$ 4 (n = 39)
Age, y, mean $\pm$ SD	75.2 $\pm$ 9.7	73.6 $\pm$ 10.7	70.7 $\pm$ 11.5
Females, n (%)	8 (42.1)	25 (37.9)	22 (56.4)
White, n (%)	17 (89.5)	59 (89.4)	33 (84.6)
HTN, n (%)	12 (63.2) <sup>a</sup>	57 (86.4)	38 (97.4)
DM, n (%)	3 (25.0)	22 (44.0)	9 (47.4)
Alcohol use, n (%)	10 (62.5)	33 (56.9)	20 (54.1)
Smokers, n (%)	1 (5.9)	3 (5.0)	7 (18.0) <sup>a</sup>
Statin use, n (%)	8 (42.1)	27 (41.5)	17 (43.6)
Lobar ICH, n (%)	8 (42.1)	25 (37.9)	24 (61.5) <sup>a</sup>

Abbreviations: DM = diabetes mellitus; HTN = hypertension; ICH = intracerebral hemorrhage.

<sup>a</sup> $p < 0.05$  in comparison with the reference group (*APOE*  $\epsilon$ 3/ $\epsilon$ 3).


$\epsilon 4$  carriers were more likely to be smokers and have ICH located in the lobar region (all  $p < 0.05$ ). There were no differences in the rates of statin use between the 3 groups. *APOE* allelic frequencies in our analysis cohort were consistent with previously observed population estimates for North American Caucasians.<sup>23</sup>

***APOE* alleles and serum lipid levels in ICH patients.** We first sought to confirm previously observed effects of *APOE* on serum lipid levels, as seen in previous population-level genome-wide association studies of lipids.<sup>17</sup> Comparisons of mean serum levels of TC, TG, LDL, and HDL before ICH by *APOE* allele status revealed an expected allelic dose-dependent increase in mean serum TC and LDL levels in  $\epsilon 4$  carriers compared with noncarriers, whereas levels of both lipid fractions were decreased in  $\epsilon 2$  carriers compared with noncarriers (TC:  $217.21 \pm 58.37$  mg/dL in  $\epsilon 4$  carriers,  $157.67 \pm 41.12$  mg/dL in  $\epsilon 2$  carriers; LDL:

$130.43 \pm 48.67$  mg/dL in  $\epsilon 4$  carriers,  $69.90 \pm 19.86$  mg/dL in  $\epsilon 2$  carriers). No associations were observed for serum TG and HDL levels, consistent with known absence of *APOE* effects on these lipid fractions.

***APOE* alleles influence 24-month pre-ICH serum lipid trends.** Temporal lipid patterns in our analysis cohort revealed a decline in both serum TC and LDL levels beginning several months preceding acute ICH occurrence consistent with observed trends seen previously in a larger cohort<sup>18</sup> (figure 2). Subgroup analysis by *APOE* carrier status revealed distinct differences in temporal serum lipid trends, visualized using Loess smoothed curves, during this time period. *APOE*  $\epsilon 4$  carriers experienced an overall decline in serum TC and LDL levels in the 24 months pre-ICH. In contrast, both serum TC and LDL trends remained relatively flat in non- $\epsilon 4$  carriers during the same time period preceding ICH (figure 3).

**Figure 2** Temporal trends in individual serum lipid fractions in ICH patients




(A–D) Loess smoothed curves of serum lipid levels (mg/dL) against time (in months) before and after ICH. Gray areas indicate standard error (SE). Time period of interest is indicated by shaded boxes ( $P_2$  0–6 months pre-ICH). \* $p < 0.0125$ , rate of change of serum lipids by Wald test for the time period  $P_2$ . ICH = intracerebral hemorrhage.

Comparisons of serum lipid trends by *APOE* allele demonstrated an overall decline in serum TC and LDL levels during the pre-ICH time period in  $\epsilon 4$  carriers compared with noncarriers ( $p = 0.049$  and  $p = 0.014$ , respectively), whereas no changes were observed in  $\epsilon 2$  carriers.

***APOE* alleles influence differential change in serum lipid trends immediately preceding ICH occurrence.** Visual inspection of the Loess smoothed curves also revealed distinct differences in temporal serum lipid trends in the 6-month time period immediately preceding ICH occurrence by *APOE* allele status. Subacute declines in mean serum TC and LDL levels beginning around 6 months pre-ICH were observed only in  $\epsilon 4$  carriers (figure 3). This accelerated decline in the 6-month

period before ICH is consistent with our previous report in a larger cohort.<sup>18</sup> Covariate-adjusted PLME was used to compare differences in serum lipid trends by *APOE* genotype in the immediate 0- to 6-month interval pre-ICH and in the antecedent interval (6–24 months pre-ICH) (table 2). *APOE*  $\epsilon 4$  carriers experienced acceleration in the rates of decline in serum TC and LDL levels in the 6 months before an acute ICH event compared with trends in the antecedent 18-month time interval. The observed association remained significant after the inclusion of potential confounders in multivariate analysis, including hypertension (table 2). Comparatively, serum TC trends were unchanged in the same 6-month time period immediately pre-ICH in both *APOE*  $\epsilon 2$  carriers and *APOE*  $\epsilon 3/\epsilon 3$  individuals. In

**Figure 3** Temporal trends in individual serum lipid fractions in ICH patients by *APOE* allele carrier status



(A–D) Loess smoothed curves of serum lipid levels (mg/dL) against time (in months) before and after ICH. Gray areas indicate standard error (SE). Time period of interest is indicated by shaded boxes ( $P_2$  0–6 months pre-ICH). \* $p < 0.0125$ , rate of change of serum lipids by Wald test for time period  $P_2$  in *APOE*  $\epsilon 2$  or  $\epsilon 4$  carrier status compared with reference (*APOE*  $\epsilon 3/\epsilon 3$ ). ICH = intracerebral hemorrhage.

**Table 2** Estimated rates of change in serum lipid levels pre-ICH by *APOE* genotype status

	Time interval pre-ICH, mo		p Value
	6-24	0-6	
<b>Total cholesterol</b>			
<i>APOE</i> ε4	-0.05	-7.30	0.0035 <sup>a</sup>
<i>APOE</i> ε3 <sup>b</sup>	-0.19	-3.79	Ref.
<i>APOE</i> ε2	-0.40	+1.72	0.43
<b>Low-density lipoprotein</b>			
<i>APOE</i> ε4	+0.09	-8.44	0.0001 <sup>a</sup>
<i>APOE</i> ε3 <sup>b</sup>	-0.02	-2.39	Ref.
<i>APOE</i> ε2	-0.40	+5.16	0.07
<b>Triglycerides</b>			
<i>APOE</i> ε4	-0.24	-6.86	0.26
<i>APOE</i> ε3 <sup>b</sup>	-0.10	-6.10	Ref.
<i>APOE</i> ε2	+0.46	-16.06	0.08
<b>High-density lipoprotein</b>			
<i>APOE</i> ε4	-0.01	-0.06	0.88
<i>APOE</i> ε3 <sup>b</sup>	+0.03	-1.11	Ref.
<i>APOE</i> ε2	-0.02	-0.69	0.65

Abbreviation: ICH = intracerebral hemorrhage.

Comparisons of rates of change in serum lipid levels (in milligrams per deciliter per month) pre-ICH between time periods 6-24 months pre-ICH and 0-6 months pre-ICH using covariate-adjusted piecewise linear mixed-effects model by *APOE* allele carrier status.

<sup>a</sup>p < 0.0125 by Wald test for comparisons between time periods.

<sup>b</sup>*APOE* ε3 consist of individuals with *APOE* ε3/ε3 genotype serving as the control group for comparison.

contrast, *APOE* ε2 carriers experienced an increase in serum LDL levels in the immediate 0- to 6-month interval pre-ICH that did not surpass statistical thresholds, whereas serum LDL levels remained flat in *APOE* ε3/ε3 individuals within the same time period. Neither temporal serum HDL nor TG trends differed by *APOE* genotype.

***APOE* alleles do not influence temporal serum lipid trends post-ICH.** Serum lipid levels remained largely depressed for TC, LDL, and HDL in the 48 months post-ICH with no difference in serum lipid trends by *APOE* carrier status during that time. Serum TG trends post-ICH demonstrate variability similar to the pre-ICH period, but no differences were observed between *APOE* ε2 and ε4 carriers or individuals with *APOE* ε3/ε3 genotype within the time period examined (figure 3).

**DISCUSSION** Our results demonstrate that temporal variation in serum lipids in ICH patients are

influenced by *APOE* allele status and differ from *APOE* associations with steady-state serum lipid levels.<sup>17</sup> *APOE* ε4 carriers experienced drops in TC and LDL levels in the 24-month period before their ICH, in comparison with non-*APOE* ε4 carriers. Furthermore, in the 6-month period immediately preceding ICH, *APOE* ε4 carriers displayed increased rates of decline in serum TC and LDL levels. This observation of genotype-specific differences in temporal serum lipid trends builds on our previous observation of subacute decline in serum TC and LDL levels before acute ICH and suggests that *APOE* gene products may exert at least some of their effect on risk of ICH through modulation of serum lipids.

Demonstration of *APOE* epsilon allele-specific effects on serum lipid trends in ICH patients raises several hypotheses regarding the role of *APOE* in ICH risk. Both ε2 and ε4 are risk factors for lobar ICH, in part, through their effects on amyloid processing.<sup>4</sup> *APOE* ε4 is also independently associated with increased risk of nonlobar ICH,<sup>4</sup> presumably through nonamyloid-related mechanisms given that cerebral amyloid angiopathy is almost universally absent from the deeper small vessels.<sup>24</sup> A growing body of evidence supports the association of hypocholesterolemia with elevated risk of ICH<sup>7-14</sup> and with progression of ICH-related phenotypes such as cerebral microbleeds.<sup>14,25</sup> This association has been hypothesized to be the result of loss in vascular integrity in low circulating cholesterol states, which predisposes toward vessel rupture in ICH, although the complex role of lipids in cellular biology, inflammation, and signalling,<sup>26-29</sup> in addition to cell membrane integrity, makes it difficult to attribute the observed associations to any one mechanism.<sup>30-33</sup>

Known *APOE* effects in lipid metabolism and vascular amyloid deposition raise the possibility that *APOE* may influence ICH risk through amyloid and nonamyloid effects. Our results seem to support the hypothesis of a nonamyloid role of *APOE* in ICH risk through the observed *APOE* genotype-specific associations with subacute serum lipid changes before primary ICH. Given that *APOE* ε4 associates with higher average TC and LDL levels, our results also raise the hypothesis that the rate of change in serum levels, rather than the baseline average, is an important determinant of ICH risk imparted by the *APOE* ε4 genotype. Furthermore, our demonstration of *APOE* allele-specific effects on temporal serum lipid trends in ICH corroborates the notion of divergent mechanistic pathways between ε2 and ε4 alleles in the pathophysiology of ICH.<sup>34,35</sup> Our observations of similar *APOE* allele-specific serum TC and LDL trends pre-ICH in subgroup analyses stratified by ICH location (lobar and nonlobar) likewise support such a notion, but our study was insufficiently

powered to detect statistically significant differences because of the small sample size.

However, caution must be exercised in making mechanistic links because of the biological complexity of the underlying disease and *APOE* pleiotropy. Based on our observation, we can only speculate as to whether serum lipid declines directly drive the process of increased vessel wall vulnerability, leading ultimately to vessel rupture and ICH or serve as a surrogate marker of a separate process affecting cerebral small vessels. Active inflammation is associated with lower serum TC and LDL levels,<sup>36</sup> whereas an *APOE* genotype-specific elevation in proinflammatory response has been observed in *APOE*  $\epsilon 4$  carriers compared with *APOE*  $\epsilon 2$  and *APOE*  $\epsilon 3$  carriers in transgenic murine models.<sup>37</sup> Thus, it is possible that the influence of *APOE* polymorphisms on temporal lipid trends in ICH may instead reflect *APOE* genotype-specific differences in innate inflammatory processes in the cerebral small vessels.

A strength of this study is the use of a unique data set combining both *APOE* genotype and longitudinal lipid data in a rigorously phenotyped ICH cohort. The additional information conferred by serum lipid variations over time both before and after primary ICH revealed *APOE* genotype-specific associations distinct from known steady-state relationships. This in turn allowed for the dissection of lipid-dependent associations of *APOE* in primary ICH risk.

There are limitations to our study. First, we had to exclude almost 40% of eligible cases identified because of the absence of *APOE* genotype data. It should be noted, however, that the analysis cohort remained representative of the larger ICH cohort, with no differences in any covariates of interest to suggest a sampling bias. Furthermore, distribution of the *APOE* alleles in our small study was also consistent with frequency estimates in the population at large. We were also unable to account completely for selection bias arising from subject-specific indications for serial serum lipid measurements, although, in our particular study cohort, previous analysis showed no differences in clinical characteristics between ICH patients with and without serum lipid data.<sup>18</sup> A third limitation was our relatively small sample size, particularly with regard to the total number of *APOE*  $\epsilon 2$  individuals, which may influence our ability to more accurately assess association with serum lipid trends in those individuals. We attempted to address this by using mixed-effect modeling to increase statistical power through additional use of interindividual change with time. Nevertheless, future studies incorporating a longitudinal design with available *APOE* genotypes and relatively frequently recorded lipid levels will be necessary to validate and confirm these results. Fourth, we were unable to exhaustively

address the broad range of all the possible external environmental factors that can influence biological variation in serum lipid levels.<sup>37</sup> We did attempt to minimize potential confounding by including these measures, where available, by including covariates of age, statin, and alcohol use in our models and using a longitudinal trial design of sufficiently long duration (4 years), which limits the effect of seasonal variations<sup>38</sup> in serum lipids. In addition, we were also unable to account for either statin dose or type and potential intermittent use. However, because the decline in both serum TC and LDL levels immediately preceding ICH occurrence were previously noted to be independent of statin use,<sup>18</sup> the differential degree of lipid lowering conferred by nuances in statin use is unlikely to contribute substantial confounding. Fifth, although there is a high likelihood that LDL may be a major mediator of TC effects seen in *APOE*  $\epsilon 4$  carriers, our study design prohibits formal mediation analysis because of violation of several assumptions needed for establishing a correctly specified mediation model. Finally, although the demonstration of temporal changes in serum lipids preceding ICH strongly suggests a correlation between serum lipid changes and ICH development, we are unable to confirm a causal relationship because of the retrospective study design.

*APOE*  $\epsilon 4$  strongly predicts pre-ICH trends in serum TC and LDL levels and the acute decline in serum TC and LDL in the 6-month period before acute ICH. Our results have implications for ongoing efforts in dissecting the role of dyslipidemia in cerebrovascular disease risk and provide novel insight regarding nonamyloid *APOE* mechanisms in ICH risk.

## AUTHOR CONTRIBUTIONS

Dr. C.-L. Phuah participated in study design, data acquisition, statistical analyses, drafting, and revision of the manuscript. M.R. Raffeld and A.M. Ayres were responsible for data collection. Drs. A. Viswanathan, M. Edip Gurol, S.M. Greenberg, and J. Rosand participated in the final editing of the manuscript. Dr. C.D. Anderson participated in the study design and funding and in the revision of the manuscript.

## STUDY FUNDING

The authors' work on this study was supported by funding from the NIH (see Disclosures). No funding entities were involved in study design, data collection, analysis, interpretation, writing of the report, or in the decision to submit the results for publication.

## DISCLOSURE

Dr. C.-L. Phuah and M.R. Raffeld report no disclosures. A.M. Ayres has received research support from NIH. Dr. M. Edip Gurol has received research support from NIH–National Institute of Neurological Disorders and Stroke. Dr. A. Viswanathan has served on a data safety monitoring board for Roche Pharmaceuticals; has served as a consultant for Athena Diagnostics; and is supported by NIH–National Institute of Neurological Disorders and Stroke K23 AG028726. Dr. S.M. Greenberg has served on the MRI Review Committee of Hoffman-Laroche and the data safety monitoring board of Quintiles; has received travel funding/speaker

honoraria from the Cerebral Amyloid Angiopathy Conference and the American Academy of Neurology; has served on the editorial boards of *Stroke*, *Frontiers in Stroke*, *Cerebrovascular Disease*, *Neurology*, and *Alzheimer's Disease and Other Dementias*; has received publishing royalties from UpToDate and MedLink; and is supported by NIH–National Institute of Neurological Disorders and Stroke U10 NS077360, R01 AG026484, and R01 NS070834. Dr. A. Biffi reports no disclosures. Dr. J. Rosand has served on the editorial boards of *Lancet Neurology* and *Stroke* and is supported by NIH–National Institute of Neurological Disorders and Stroke U01 NS069208, R01 NS073344, and R01 NS059727. Dr. C.D. Anderson has received research support from Biogen Idec, Inc., and the American Brain Foundation and is supported by NIH–National Institute of Neurological Disorders and Stroke K23 NS 086873. Go to [Neurology.org/ng](http://Neurology.org/ng) for full disclosure forms.

Received January 15, 2016. Accepted in final form May 3, 2016.

## REFERENCES

- Krishnamurthi RV, Moran AE, Forouzanfar MH, et al. The global burden of hemorrhagic stroke: a summary of findings from the GBD 2010 study. *Glob Heart* 2014;9:101–106.
- Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry* 2014;85:660–667.
- van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *Lancet Neurol* 2010;9:167–176.
- Biffi A, Sonni A, Anderson CD, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. *Ann Neurol* 2010;68:934–943.
- Devan WJ, Falcone GJ, Anderson CD, et al. Heritability estimates identify a substantial contribution to risk and outcome of intracerebral hemorrhage. *Stroke* 2013;44:1578–1583.
- Brouwers HB, Biffi A, Ayres AM, et al. Apolipoprotein E genotype predicts hematoma expansion in lobar intracerebral hemorrhage. *Stroke* 2012;43:1490–1495.
- Raffeld MR, Biffi A, Battey TWK, et al. APOE ε4 and lipid levels affect risk of recurrent nonlobar intracerebral hemorrhage. *Neurology* 2015;85:1–8.
- Woo D, Deka R, Falcone GJ, et al. Apolipoprotein E, statins, and risk of intracerebral hemorrhage. *Stroke* 2013;44:3013–3017.
- Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. *Stroke* 2013;44:1833–1839.
- Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. *Lancet* 2004;363:757–767.
- Segal AZ, Chiu RI, Eggleston-Sexton PM, Beiser A, Greenberg SM. Low cholesterol as a risk factor for primary intracerebral hemorrhage: a case-control study. *Neuroepidemiol* 1999;18:185–193.
- Woo D, Kissela BM, Khoury JC, et al. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. *Stroke* 2004;35:1360–1364.
- Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;366:1267–1278.
- Wieberdink RG, Poels MM, Vernooij MW, et al. Serum lipid levels and the risk of intracerebral hemorrhage: the Rotterdam Study. *Arteriocler Thromb Vasc Biol* 2011;31:2982–2989.
- Rodriguez-Luna D, Rubeira M, Ribo M, et al. Serum low-density lipoprotein cholesterol level predicts hematoma growth and clinical outcome after acute intracerebral hemorrhage. *Stroke* 2011;42:2447–2452.
- Mustanoja S, Strbian D, Putaala J, et al. Association of prestroke statin use and lipid levels with outcome of intracerebral hemorrhage. *Stroke* 2013;44:2330–2332.
- Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 2010;466:707–713.
- Phuah CL, Raffeld MR, Ayres AM, et al. Subacute decline in serum lipids precedes the occurrence of primary intracerebral hemorrhage. *Neurology* 2016;86:2034–2041.
- O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. *N Engl J Med* 2000;342:240–245.
- Man EB, Bettcher PG, Cameron CM, Peters JP. Plasma amino acids, nitrogen and serum lipids of surgical patients. *J Clin Invest* 1946;25:701–708.
- Gore JM, Goldberg RJ, Matsumoto AS, Castelli WP, McNamara AB, Dalen JE. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. *Am J Cardiol* 1984;54:722–725.
- Naumova EN, Must A, Laird NM. Tutorial in biostatistics: evaluating the impact of “critical periods” in longitudinal studies of growth using piecewise mixed effects models. *Int J Epidemiol* 2001;30:1332–1341.
- Ordovas JM, Litwack-Klein L, Wilson PWF, Schaefer MM, Schaefer EJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of ApoE1 and ApoE5 isoforms. *J Lipid Res* 1987;28:371–380.
- Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. *Stroke* 2002;33:1190–1196.
- Romero JR, Preis SR, Beiser A, et al. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study. *Stroke* 2014;45:1492–1494.
- Stables MJ, Gilroy DW. Old and new generation lipid mediators in acute inflammation and resolution. *Prog Lipid Res* 2011;50:35–51.
- Phillips MC. Molecular mechanisms of cellular cholesterol efflux. *J Biol Chem* 2014;289:24020–24029.
- Ledeer RW, Wu G. Nuclear sphingolipids: metabolism and signaling. *J Lipid Res* 2008;49:1176–1186.
- Ohanian J, Ohanian V. Sphingolipids in mammalian cell signalling. *Cell Mol Life Sci* 2001;58:2053–2068.
- Ooneda G, Yoshida Y, Suzuki K, Sekiguchi T. Morphogenesis of plasmatic arterionecrosis as the cause of hypertensive intracerebral hemorrhage. *Virchows Arch A Pathol Pathol Anat* 1973;361:31–38.
- Russell RW. How does blood pressure cause stroke? *Lancet* 1974;2:1283–1285.
- Konishi M, Terao A, Doi M, et al. Osmotic resistance and cholesterol content of the erythrocyte membrane in cerebral hemorrhage. *Igaku No Ayumi* 1982;120:30–32.



33. Kroes J, Ostwald R. Erythrocyte membranes—effect of increased cholesterol content on permeability. *Biochim Biophys Acta* 1971;249:647–650.
34. McCarron MO, Nicoll JA, Stewart J, et al. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. *J Neuropathol Exp Neurol* 1999;58:711–718.
35. Greenberg SM, Vonsattel JP, Segal AZ, et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. *Neurology* 1998;50:961–965.
36. McGullicuddy FC, de la Llera Moy M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. *Circulation* 2009;119:1135–1145.
37. Jofre-Monseny L, Loboda A, Wagner AE, et al. Effects of apoE genotype on macrophage inflammation and heme oxygenase-1 expression. *Biochem Biophys Res Commun* 2007;357:319–324.
38. Durrington PN. Biological variation in serum lipid concentrations. *Scand J Clin Lab Invest Suppl* 1990;198:86–91.

# Neurology<sup>®</sup> Genetics

***APOE* polymorphisms influence longitudinal lipid trends preceding intracerebral  
hemorrhage**

Chia-Ling Phuah, Miriam R. Raffeld, Alison M. Ayres, et al.

*Neurol Genet* 2016;2;

DOI 10.1212/NXG.0000000000000081

**This information is current as of June 23, 2016**

*Neurol Genet* is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright © 2016 American Academy of Neurology. All rights reserved. Online ISSN: 2376-7839.



<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://ng.neurology.org/content/2/4/e81.full.html">http://ng.neurology.org/content/2/4/e81.full.html</a>
<b>Supplementary Material</b>	Supplementary material can be found at: <a href="http://ng.neurology.org/content/suppl/2016/06/23/2.4.e81.DC1">http://ng.neurology.org/content/suppl/2016/06/23/2.4.e81.DC1</a>
<b>References</b>	This article cites 38 articles, 15 of which you can access for free at: <a href="http://ng.neurology.org/content/2/4/e81.full.html##ref-list-1">http://ng.neurology.org/content/2/4/e81.full.html##ref-list-1</a>
<b>Citations</b>	This article has been cited by 3 HighWire-hosted articles: <a href="http://ng.neurology.org/content/2/4/e81.full.html##otherarticles">http://ng.neurology.org/content/2/4/e81.full.html##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All Genetics</b> <a href="http://ng.neurology.org/cgi/collection/all_genetics">http://ng.neurology.org/cgi/collection/all_genetics</a> <b>Cohort studies</b> <a href="http://ng.neurology.org/cgi/collection/cohort_studies">http://ng.neurology.org/cgi/collection/cohort_studies</a> <b>Intracerebral hemorrhage</b> <a href="http://ng.neurology.org/cgi/collection/intracerebral_hemorrhage">http://ng.neurology.org/cgi/collection/intracerebral_hemorrhage</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://ng.neurology.org/misc/about.xhtml#permissions">http://ng.neurology.org/misc/about.xhtml#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://ng.neurology.org/misc/addir.xhtml#reprintsus">http://ng.neurology.org/misc/addir.xhtml#reprintsus</a>

*Neurol Genet* is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright © 2016 American Academy of Neurology. All rights reserved. Online ISSN: 2376-7839.

